Journal: Nuclear medicine and biology

Article Title: Automated Clinical Production, Dosimetry Estimates and Preclinical Safety Considerations for Clinical Translation of a SOAT1-Targeted PET Imaging Agent

doi: 10.1016/j.nucmedbio.2026.109681

Figure Lengend Snippet: Left: Representative semi-preparative HPLC trace from a radiosynthesis of [ 11 C]nevanimibe. “Cut peak” represents the period of product collection into the dilution flask (UV trace: top, radiochemical trace: bottom, t R = 12 min). Right: Representative analytical HPLC trace of formulated 11 C-nevanimibe (UV trace: top, radiochemical trace: bottom, t R = 5.3 min). The labeling precursor, 12 C-nevanimibe, and 11 C-nevanimibe are labeled, and ascorbic acid in the formulation is apparent early in the analytical HPLC trace (t R = 0.65 min).

Article Snippet: The crude mixture was then purified using reverse-phase semi-preparative HPLC (column: Phenomenex Luna C18(2) 10 μm 100 × 10 mm 100 Å; mobile phase: 70% EtOH 10 mM NaOAc 1 mM L -ascorbic acid; flow rate: 2 mL/min) (for a representative trace, see Figure 2 ).

Techniques: Labeling, Formulation